Inflammation And Pain Post Cataract Surgery Market Expected to Gain Momentum Through 2034, According to DelveInsight

DelveInsight's "Inflammation And Pain Post Cataract Surgery Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Inflammation And Pain Post Cataract Surgery, historical and forecasted epidemiology as well as the Inflammation And Pain Post Cataract Surgery market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Inflammation And Pain Post Cataract Surgery market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Inflammation And Pain Post Cataract Surgery Market Forecast
https://www.delveinsight.com/sample-request/inflammation-and-pain-post-cataract-surgery-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Inflammation And Pain Post Cataract Surgery Market Report:
• The Inflammation And Pain Post Cataract Surgery market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In December 2024, China-based VivaVision Biotech plans to advance its non-steroidal therapy, VVN461-CS-201 (VVN461), into a Phase III trial after the candidate successfully met the primary endpoint in a Phase II U.S. study for treating post-operative inflammation following cataract surgery. CEO Wang Shen highlighted the Phase II trial (NCT06164743) results, noting that the therapy led to "reductions in inflammation and ocular pain as early as day three," emphasizing that these outcomes "provide a solid foundation to progress toward a Phase III clinical trial of VVN461 in the U.S."
• The market for managing inflammation and pain after cataract surgery is currently led by companies such as Ocular Therapeutix, Alcon, and Eyenovia, with their products DEXTENZA, INVELTYS, and APP13007, respectively.
• The US FDA has approved four topical ocular NSAIDs for treating postoperative inflammation following cataract surgery. These are VOLTAREN (diclofenac sodium ophthalmic solution), ACULAR, NEVANAC (nepafenac ophthalmic suspension), and XIBROM (bromfenac ophthalmic solution).
• According to DelveInsight's analysis, approximately 20 million Americans aged 40 and older have cataracts in one or both eyes, with about 6 million having undergone lens removal surgery. Additionally, their analysis indicates that chronic or recurrent inflammation, including cystoid macular edema, affects about 0.1% to 2% of patients after routine cataract surgery.
• According to a 2019 analysis, 2,200 cataract surgeries were performed in the US, and approximately 40 of these cases experienced post-operative iritis lasting more than one month.
• Our analysis indicates that cataract surgery is the most frequently performed elective surgical procedure in the UK, with approximately 330,000 cataract operations conducted annually in England alone.
• Key Inflammation And Pain Post Cataract Surgery Companies: Ocular Therapeutix, Alcon, Eyenovia, VivaVision Biotech, Oculis, Salvat, and others
• Key Inflammation And Pain Post Cataract Surgery Therapies: DEXTENZA (dexamethasone), INVELTYS (loteprednol etabonate ophthalmic suspension), APP13007 (clobetasol propionate), VVN461, OCS-01, Dexamethasone Ophthalmic Suspension, Clobetasol Propionate, and others
• The Inflammation And Pain Post Cataract Surgery market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Inflammation And Pain Post Cataract Surgery pipeline products will significantly revolutionize the Inflammation And Pain Post Cataract Surgery market dynamics.

Inflammation And Pain Post Cataract Surgery Overview
Inflammation and pain following cataract surgery are common postoperative complications that can affect patient recovery and overall outcomes. Understanding these issues is crucial for effective management and improved patient care.

Get a Free sample for the Inflammation And Pain Post Cataract Surgery Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/inflammation-and-pain-post-cataract-surgery-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Inflammation And Pain Post Cataract Surgery Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Inflammation And Pain Post Cataract Surgery Epidemiology Segmentation:
The Inflammation And Pain Post Cataract Surgery market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Inflammation And Pain Post Cataract Surgery
• Prevalent Cases of Inflammation And Pain Post Cataract Surgery by severity
• Gender-specific Prevalence of Inflammation And Pain Post Cataract Surgery
• Diagnosed Cases of Episodic and Chronic Inflammation And Pain Post Cataract Surgery

Download the report to understand which factors are driving Inflammation And Pain Post Cataract Surgery epidemiology trends @ Inflammation And Pain Post Cataract Surgery Epidemiology Forecast
https://www.delveinsight.com/sample-request/inflammation-and-pain-post-cataract-surgery-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Inflammation And Pain Post Cataract Surgery Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Inflammation And Pain Post Cataract Surgery market or expected to get launched during the study period. The analysis covers Inflammation And Pain Post Cataract Surgery market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Inflammation And Pain Post Cataract Surgery Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Inflammation And Pain Post Cataract Surgery Therapies and Key Companies
• DEXTENZA (dexamethasone): Ocular Therapeutix
• INVELTYS (loteprednol etabonate ophthalmic suspension): Alcon
• APP13007 (clobetasol propionate): Eyenovia
• VVN461: VivaVision Biotech
• OCS-01: Oculis
• Dexamethasone Ophthalmic Suspension: Oculis
• Clobetasol Propionate: Salvat

Discover more about therapies set to grab major Inflammation And Pain Post Cataract Surgery market share @ Inflammation And Pain Post Cataract Surgery Treatment Landscape
https://www.delveinsight.com/sample-request/inflammation-and-pain-post-cataract-surgery-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Inflammation And Pain Post Cataract Surgery Market Drivers
• Rising Number of Cataract Surgeries:
• Technological Advancements
• Regulatory Approvals
• Awareness and Diagnosis
• Healthcare Expenditure

Inflammation And Pain Post Cataract Surgery Market Barriers
• Side Effects
• High Costs
• Regulatory Hurdles
• Market Competition
• Patient Non-compliance

Scope of the Inflammation And Pain Post Cataract Surgery Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Inflammation And Pain Post Cataract Surgery Companies: , and others
• Key Inflammation And Pain Post Cataract Surgery Therapies: DEXTENZA (dexamethasone), INVELTYS (loteprednol etabonate ophthalmic suspension), APP13007 (clobetasol propionate), VVN461, OCS-01, Dexamethasone Ophthalmic Suspension, Clobetasol Propionate, and others
• Inflammation And Pain Post Cataract Surgery Therapeutic Assessment: Inflammation And Pain Post Cataract Surgery current marketed and Inflammation And Pain Post Cataract Surgery emerging therapies
• Inflammation And Pain Post Cataract Surgery Market Dynamics: Inflammation And Pain Post Cataract Surgery market drivers and Inflammation And Pain Post Cataract Surgery market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Inflammation And Pain Post Cataract Surgery Unmet Needs, KOL's views, Analyst's views, Inflammation And Pain Post Cataract Surgery Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.